Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer

Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer

BackgroundResponse rates to single agent immune checkpoint blockade in unselected pretreated HER2−negative metastatic breast cancer (MBC) are low. However, they may be augmented when combined with chemotherapy.MethodsWe conducted a single-arm, phase II study of patients with triple negative (TN) or...

Full description

Bibliographic Details
Main Authors: Ami N Shah, Lisa Flaum, Irene Helenowski, Cesar A Santa-Maria, Sarika Jain, Alfred Rademaker, Valerie Nelson, Dean Tsarwhas, Massimo Cristofanilli, William Gradishar
Format: Article
Language:English
Published: BMJ Publishing Group 2020-06-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/1/e000173.full

Internet

https://jitc.bmj.com/content/8/1/e000173.full

Similar Items